Skip to content

Protara Therapeutics, Inc.: 10-Q filed 2020-11-12

What Protara Therapeutics, Inc. reported in its quarterly report filed 2020-11-12 (fiscal Q3 2020): 33 published measures, 84 facts as tagged in accession 0001213900-20-036343.

This filing

Form
10-Q (quarterly report)
Filed
2020-11-12
Fiscal period
fiscal Q3 2020
Accession
0001213900-20-036343 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Protara Therapeutics, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2020-09-30198,907,257USD
At 2019-12-311,222,484USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2020-09-304,281,494USD
At 2019-12-313,350,443USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2020-09-30194,625,763USD
At 2020-06-3059,430,533USD
At 2020-03-3164,741,841USD
At 2019-12-31-2,127,959USD
At 2019-09-30284,908USD
At 2019-06-301,999,852USD
At 2019-03-313,326,065USD
At 2018-12-314,777,239USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2020-09-30165,904,797USD
At 2019-12-31564,124USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-7,970,085USD92
2020-01-01 to 2020-09-30-25,170,372USD274
2019-07-01 to 2019-09-30-2,354,083USD92
2019-01-01 to 2019-09-30-5,310,814USD273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2020-01-01 to 2020-09-30-16,641,088USD274
2019-01-01 to 2019-09-30-3,922,307USD273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2020-01-01 to 2020-09-30373,340USD274
2019-01-01 to 2019-09-30429,138USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2020-01-01 to 2020-09-30178,686,359USD274
2019-01-01 to 2019-09-30499,999USD273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2020-01-01 to 2020-09-303,345,402USD274
2019-01-01 to 2019-09-30-429,138USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2020-09-30-37,952,032USD
At 2019-12-31-12,781,660USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2020-09-30760,548USD
At 2019-12-31458,591USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2020-07-01 to 2020-09-302,780,802USD92
2020-01-01 to 2020-09-307,407,331USD274
2019-07-01 to 2019-09-30139,140USD92
2019-01-01 to 2019-09-30318,484USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-8,062,179USD92
2020-01-01 to 2020-09-30-25,487,679USD274
2019-07-01 to 2019-09-30-2,354,083USD92
2019-01-01 to 2019-09-30-5,310,814USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2020-09-30167,115,054USD
At 2019-12-31763,893USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2020-09-303,886,773USD
At 2019-12-313,350,443USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2020-09-301,912,553USD
At 2019-12-31715,653USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2020-09-3029,367,213USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2020-07-01 to 2020-09-308,062,179USD92
2020-01-01 to 2020-09-3025,487,679USD274
2019-07-01 to 2019-09-302,354,083USD92
2019-01-01 to 2019-09-305,310,814USD273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2020-07-01 to 2020-09-302,796,214USD92
2020-01-01 to 2020-09-308,330,727USD274
2019-07-01 to 2019-09-301,098,617USD92
2019-01-01 to 2019-09-303,163,179USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2020-09-3010,521,840shares
At 2019-12-312,627,533shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2020-09-30165,954,797USD
At 2019-12-31564,124USD
At 2019-09-301,698,506USD
At 2018-12-315,549,952USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2020-09-30232,567,265USD
At 2019-12-3110,651,073USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2020-09-30553,660USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2020-09-301,664,442USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2020-09-301,569,348USD
At 2019-12-312,634,790USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2020-09-301,160,257USD
At 2019-12-3178,057USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-7,970,085USD92
2020-04-01 to 2020-06-30-7,140,030USD91
2020-01-01 to 2020-03-31-10,060,257USD91
2019-07-01 to 2019-09-30-2,354,083USD92
2019-04-01 to 2019-06-30-1,428,675USD91
2019-01-01 to 2019-03-31-1,528,056USD90

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2020-07-01 to 2020-09-305,265,965USD92
2020-01-01 to 2020-09-3017,156,952USD274
2019-07-01 to 2019-09-301,255,466USD92
2019-01-01 to 2019-09-302,147,635USD273

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2020-01-01 to 2020-09-3071,383USD274

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2020-07-01 to 2020-09-3092,094USD92
2020-01-01 to 2020-09-30317,307USD274

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2020-01-01 to 2020-09-3026,353USD274

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2020-01-01 to 2020-09-3073,570,660USD274

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2020-01-01 to 2020-09-301,196,900USD274
2019-01-01 to 2019-09-30-152,239USD273

Inspect the source

Entity
Protara Therapeutics, Inc. / CIK 0001359931
Captured
2026-09-20T07:55:59.662Z
SEC response SHA-256
73c5c8e9513bdc55c707e83d9669fc2bd4dbb1b11805f8d13591997b9e86c1c4

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001359931.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))